Cerebral Small Vessel Disease and Depression Among Intracerebral Hemorrhage Survivors.

Aged Aged, 80 and over Antidepressive Agents / therapeutic use Biomarkers Cerebral Amyloid Angiopathy / complications Cerebral Hemorrhage / complications Cerebral Small Vessel Diseases / diagnostic imaging Depression / drug therapy Depressive Disorder, Treatment-Resistant / drug therapy Female Humans Hypertension / complications Longitudinal Studies Magnetic Resonance Imaging Male Middle Aged Neuroimaging Survival Analysis Tomography, X-Ray Computed Treatment Outcome
cerebral hemorrhage depression magnetic resonance imaging siderosis survivors white matter

Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
02 2022
Historique:
pubmed: 1 10 2021
medline: 19 2 2022
entrez: 30 9 2021
Statut: ppublish

Résumé

Intracerebral hemorrhage (ICH) is an acute manifestation of cerebral small vessel disease (CSVD), usually cerebral amyloid angiopathy or hypertensive arteriopathy. CSVD-related imaging findings are associated with increased depression incidence in the general population. Neuroimaging may, therefore, provide insight on depression risk among ICH survivors. We sought to determine whether CSVD CT and magnetic resonance imaging markers are associated with depression risk (before and after ICH), depression remission, and effectiveness of antidepressant treatment. We analyzed data from the single-center longitudinal ICH study conducted at Massachusetts General Hospital. Participants underwent CT and magnetic resonance imaging imaging and were followed longitudinally. We extracted information for neuroimaging markers of CSVD subtype and severity. Outcomes of interest included pre-ICH depression, new-onset depression after ICH, resolution of depressive symptoms, and response to antidepressant treatment. We followed 612 ICH survivors for a median of 47.2 months. Multiple CSVD-related markers were associated with depression risk. Survivors of cerebral amyloid angiopathy-related lobar ICH were more likely to be diagnosed with depression before ICH (odds ratio, 1.68 [95% CI, 1.14-2.48]) and after ICH (sub-hazard ratio, 1.52 [95% CI, 1.12-2.07]), less likely to achieve remission of depressive symptoms (sub-hazard ratio, 0.69 [95% CI, 0.51-0.94]), and to benefit from antidepressant therapy ( CSVD severity is associated with depression diagnosis, both before and after ICH. Cerebral amyloid angiopathy-related ICH survivors are more likely to experience depression (both before and after ICH) than patients diagnosed with hypertensive arteriopathy-related ICH, and more likely to report persistent depressive symptoms and display resistance to antidepressant treatment.

Sections du résumé

BACKGROUND AND PURPOSE
Intracerebral hemorrhage (ICH) is an acute manifestation of cerebral small vessel disease (CSVD), usually cerebral amyloid angiopathy or hypertensive arteriopathy. CSVD-related imaging findings are associated with increased depression incidence in the general population. Neuroimaging may, therefore, provide insight on depression risk among ICH survivors. We sought to determine whether CSVD CT and magnetic resonance imaging markers are associated with depression risk (before and after ICH), depression remission, and effectiveness of antidepressant treatment.
METHODS
We analyzed data from the single-center longitudinal ICH study conducted at Massachusetts General Hospital. Participants underwent CT and magnetic resonance imaging imaging and were followed longitudinally. We extracted information for neuroimaging markers of CSVD subtype and severity. Outcomes of interest included pre-ICH depression, new-onset depression after ICH, resolution of depressive symptoms, and response to antidepressant treatment.
RESULTS
We followed 612 ICH survivors for a median of 47.2 months. Multiple CSVD-related markers were associated with depression risk. Survivors of cerebral amyloid angiopathy-related lobar ICH were more likely to be diagnosed with depression before ICH (odds ratio, 1.68 [95% CI, 1.14-2.48]) and after ICH (sub-hazard ratio, 1.52 [95% CI, 1.12-2.07]), less likely to achieve remission of depressive symptoms (sub-hazard ratio, 0.69 [95% CI, 0.51-0.94]), and to benefit from antidepressant therapy (
CONCLUSIONS
CSVD severity is associated with depression diagnosis, both before and after ICH. Cerebral amyloid angiopathy-related ICH survivors are more likely to experience depression (both before and after ICH) than patients diagnosed with hypertensive arteriopathy-related ICH, and more likely to report persistent depressive symptoms and display resistance to antidepressant treatment.

Identifiants

DOI: 10.1161/STROKEAHA.121.035488 PMID: 34587793 PMC: PMC8792169
pubmed: 34587793
doi: 10.1161/STROKEAHA.121.035488
pmc: PMC8792169
mid: NIHMS1740449
doi:

Substances chimiques

Antidepressive Agents 0
Biomarkers 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

523-531

Subventions

Organisme : NIA NIH HHS
ID : R01 AG026484
Pays : United States
Organisme : NHGRI NIH HHS
ID : UM1 HG008895
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS083711
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005134
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS103924
Pays : United States
Organisme : American Heart Association-American Stroke Association
ID : 18SFRN34110082
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG047975
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS100816
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS093870
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS036695
Pays : United States
Organisme : NINDS NIH HHS
ID : R24 NS092983
Pays : United States

Références

World J Radiol. 2020 May 28;12(5):48-67
pubmed: 32549954
Neurology. 2019 Jun 11;92(24):1146-1156
pubmed: 31142635
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
J Clin Neurol. 2011 Mar;7(1):1-9
pubmed: 21519520
JAMA Neurol. 2016 Aug 1;73(8):994-1001
pubmed: 27366898
J Am Geriatr Soc. 1983 Dec;31(12):721-7
pubmed: 6418786
JAMA Neurol. 2020 Aug 31;:
pubmed: 32865558
Psychol Med. 2012 Feb;42(2):359-70
pubmed: 21835088
Nat Rev Neurol. 2020 Jan;16(1):30-42
pubmed: 31827267
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):660-7
pubmed: 24262916
Neurology. 2017 Jun 13;88(24):2260-2267
pubmed: 28515266
Int J Geriatr Psychiatry. 1999 Oct;14(10):858-65
pubmed: 10521885
Stroke. 2017 Feb;48(2):e30-e43
pubmed: 27932603
J Geriatr Psychiatry Neurol. 2014 Mar;27(1):24-32
pubmed: 24381231
BMC Med. 2016 Nov 3;14(1):161
pubmed: 27806704
Br J Math Stat Psychol. 2002 May;55(Pt 1):27-39
pubmed: 12034010
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):619-24
pubmed: 17717021
JAMA Psychiatry. 2017 Jul 1;74(7):729-739
pubmed: 28564681
JAMA Neurol. 2016 Aug 1;73(8):969-76
pubmed: 27295605
Arch Gen Psychiatry. 1997 Oct;54(10):915-22
pubmed: 9337771
Brain. 2016 Oct;139(Pt 10):2694-2705
pubmed: 27497491
Neurology. 2018 Jan 9;90(2):e119-e126
pubmed: 29247070
Alzheimers Dement (Amst). 2017 Dec 06;10:112-120
pubmed: 29780860
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Neurology. 2021 Jan 12;96(2):e182-e192
pubmed: 33067403
Mol Psychiatry. 2013 Sep;18(9):963-74
pubmed: 23439482
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
J Stroke. 2017 Jan;19(1):3-10
pubmed: 28178408
Neurosci Biobehav Rev. 2018 Jul;90:164-173
pubmed: 29656031
NeuroRehabilitation. 2017;41(1):179-187
pubmed: 28505996
Brain Res Rev. 2009 Dec 11;62(1):19-32
pubmed: 19744522
JAMA. 2015 Sep 1;314(9):904-12
pubmed: 26325559
Neurology. 2014 Sep 30;83(14):1228-34
pubmed: 25165388
Psychiatry Res Neuroimaging. 2016 Jul 30;253:1-6
pubmed: 27254084
Am J Geriatr Psychiatry. 2015 May;23(5):525-35
pubmed: 25151438

Auteurs

Juan Pablo Castello (JP)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Henry and Allison McCance Center for Brain Health (J.P.C., J.R.A., C.K., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston.

Marco Pasi (M)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Univ.Lille, Inserm, CHU Lille, U 1172 - LilNCog - Lille Neuroscience and Cognition, France (M.P.).
ORCID: 0000-0001-9976-2459

Patryk Kubiszewski (P)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.

Jessica R Abramson (JR)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Henry and Allison McCance Center for Brain Health (J.P.C., J.R.A., C.K., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston.
ORCID: 0000-0003-0622-7989

Andreas Charidimou (A)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
ORCID: 0000-0001-5891-337X

Christina Kourkoulis (C)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Henry and Allison McCance Center for Brain Health (J.P.C., J.R.A., C.K., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston.

Zora DiPucchio (Z)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.

Kristin Schwab (K)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.

Christopher D Anderson (CD)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Henry and Allison McCance Center for Brain Health (J.P.C., J.R.A., C.K., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston.
ORCID: 0000-0002-0053-2002

M Edip Gurol (ME)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
ORCID: 0000-0002-2169-4457

Steven M Greenberg (SM)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
ORCID: 0000-0003-1792-8887

Jonathan Rosand (J)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Henry and Allison McCance Center for Brain Health (J.P.C., J.R.A., C.K., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston.
ORCID: 0000-0002-1014-9138

Anand Viswanathan (A)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.

Alessandro Biffi (A)

Department of Neurology (J.P.C., M.P., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Hemorrhagic Stroke Research Program (J.P.C., P.K., J.R.A., A.C., C.K., Z.D., K.S., C.D.A., M.E.G., S.M.G., J.R., A.V., A.B.), Massachusetts General Hospital, Boston.
Henry and Allison McCance Center for Brain Health (J.P.C., J.R.A., C.K., C.D.A., J.R., A.B.), Massachusetts General Hospital, Boston.
Department of Psychiatry (A.B.), Massachusetts General Hospital, Boston.
ORCID: 0000-0001-7063-455X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Psychoanaleptiques › Antidépresseurs › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles de l'homéostasie des protéines › Amyloïdose › Angiopathie amyloïde cérébrale › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Hémorragie › Hémorragies intracrâniennes › Hémorragie cérébrale › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Angiopathies intracrâniennes › Maladies des petits vaisseaux cérébraux › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Émotions › Dépression › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Trouble dépressif › Trouble dépressif résistant aux traitements › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Maladies cardiovasculaires › Maladies vasculaires › Hypertension artérielle › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Imagerie par résonance magnétique › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Techniques d'investigation › Neuroimagerie › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Imagerie diagnostique › Tomographie › Tomographie à rayons X › Tomodensitométrie › Cerebral Small Vessel Disease and Depression...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Cerebral Small Vessel Disease and Depression...